Mr. Stephen Lockyer reports

MEDX ANNOUNCES EXTENSION OF NON-BROKERED PRIVATE PLACEMENT

Further to the press release dated April 7, 2025, when MedX Health Corp. announced the initial closing of the non-brokered private placement to accredited investors originally announced in its press release dated Feb. 25, 2025, MedX Health has made application to the TSX Venture Exchange for an extension of 30 days to June 6, 2025, within which to effect further closings on this private placement. The initial closing, effective April 3, 2025, comprised the issuance of 13.5 million units (as described in detail in the company's press release dated April 7, 2025) and raised cash proceeds of $945,000. With the extension of the final date for this placement, it is anticipated that further closings will take place, for up to a maximum of a further 22,214,285 units at seven cents per unit, to raise up to a further $1,555,000. As previously announced, it is anticipated that, subject to compliance with relevant regulatory provisions, certain insiders may participate in this placement at a subsequent closing, though to not more than 25 per cent of the total funds raised. Funds raised in this placement will be directed toward continuing development of the company's leading-edge SIAscopy on the DermSecure telemedicine platform, toward building out the launch of its technology into the occupational health marketplace and for general corporate purposes.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on the DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also embedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485 certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner with its software, and then create real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.

We seek Safe Harbor.